Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases

• Published in: Journal of the American Academy of Dermatology Vol. 74; no. 6; pp. 1153 - 1159
• Main Authors: Faivre, Coline, MD, Villani, Axel Patrice, MD, Aubin, François, MD, PhD, Lipsker, Dan, MD, PhD, Bottaro, Martine, MD, Cohen, Jean-David, MD, Durupt, François, MD, PhD, Jeudy, Géraldine, MD, Sbidian, Emilie, MD, PhD, Toussirot, Eric, MD, PhD, Badot, Valérie, MD, PhD, Barbarot, Sébastien, MD, PhD, Debarbieux, Sébastien, MD, Delaporte, Emmanuel, MD, PhD, Goegebeur, Guetty, MD, Morel, Jacques, MD, PhD, Nassif, Aude, MD, Duru, Gérard, PhD, Jullien, Denis, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2016; Elsevier
• Subjects: Adalimumab - adverse effects; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Antibodies, Monoclonal, Humanized - adverse effects; Arthritis - drug therapy; biologic agents; Biological Products - adverse effects; Crohn Disease - chemically induced; Crohn Disease - drug therapy; Dermatology; Drug Eruptions - etiology; Drug Substitution; Etanercept - adverse effects; Female; hidradenitis suppurativa; Hidradenitis Suppurativa - chemically induced; Human health and pathology; Humans; Infliximab - adverse effects; Life Sciences; Male; Middle Aged; paradoxical reactions; Psoriasis - chemically induced; Psoriasis - drug therapy; Recurrence; Retrospective Studies; Rituximab - adverse effects; tumor necrosis factor-alfa inhibitors; Withholding Treatment; Young Adult; IL; biologic agents; tumor necrosis factor; paradoxical reactions; hidradenitis suppurativa; HS; interleukin; TNF; tumor necrosis factor-alfa inhibitors; BA
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2016.01.018

Background Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported. Objective We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA. Methods This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA. Results We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients. Limitations Retrospective nature and lack of complete follow-up for some patients are limitations. Conclusion HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched.